Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'DOSE INTENSITY' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 369 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Cuomo, AM; Della Cuna, FSR; Baiardi, P; Torazzo, R; Preti, P; Della Cuna, GR
      Three conventional-drug combination (ifosfamide, carboplatin, etoposide-ICE regimen) in advanced non-small cell lung cancer (NSCLC)

      JOURNAL OF CHEMOTHERAPY
    2. Rueda, A; Sevilla, I; Guma, J; Ribelles, N; Miramon, J; De Las Nieves, MA; Marquez, A; Alba, E
      Secondary prophylactic C-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD

      LEUKEMIA & LYMPHOMA
    3. Flechon, A; Culine, S; Droz, JP
      Intensive and timely chemotherapy, the key of success in testicular cancer

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    4. Bacci, G; Ferrari, S; Longhi, A; Forni, C; Giacomini, S; Lari, S; Versari, M
      Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy

      ONCOLOGY REPORTS
    5. Verrill, M
      Anthracyclines in breast cancer: therapy and issues of toxicity

      BREAST
    6. Monfardini, S
      Medical oncology

      EUROPEAN JOURNAL OF CANCER
    7. Bell, R
      Duration of therapy in metastatic breast cancer: management using Herceptin (R)

      ANTI-CANCER DRUGS
    8. Takagi, T; Sawamura, M; Sezaki, T; Kashimura, M; Tsuchiya, J; Hotta, T; Ogawa, N; Hirashima, K
      Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM)

      SUPPORTIVE CARE IN CANCER
    9. Huddart, RA; Lau, FN; Guerrero-Urbano, T; Jay, G; Norman, A; Horwich, A; Dearnaley, DP
      Accelerated chemotherapy in the treatment of urothelial cancer

      CLINICAL ONCOLOGY
    10. Sanguineti, G; Del Mastro, L; Guenzi, M; Ricci, P; Cavallari, M; Canavese, G; Stevani, I; Venturini, M
      Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery

      ANNALS OF ONCOLOGY
    11. Paulussen, M; Ahrens, S; Lehnert, M; Taeger, D; Hense, HW; Wagner, A; Dunst, J; Harms, D; Reiter, A; Henze, G; Niemeyer, C; Gobel, U; Kremens, B; Folsch, UR; Aulitzky, WE; Voute, PA; Zoubek, A; Jurgens, H
      Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study

      ANNALS OF ONCOLOGY
    12. Hidaka, T; Fujimura, M; Sakai, M; Saito, S
      Macrophage colony-stimulating factor prevents febrile neutropenia induced by chemotherapy

      JAPANESE JOURNAL OF CANCER RESEARCH
    13. Im, DD; McGuire, WP; Rosenshein, NB
      Contemporary management of ovarian cancer

      OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
    14. Bradstock, K; Matthews, J; Young, G; Lowenthal, R; Baxter, H; Arthur, C; Bashford, J; Brighton, T; Cannell, P; Dunlop, L; Durrant, S; Enno, A; Eliadis, P; Gill, D; Gillett, A; Gottlieb, D; Januszewicz, H; Joshua, D; Leahy, M; Schwarer, A; Taylor, K
      Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia

      LEUKEMIA
    15. Hutchins, LF; Arick, CL
      Adjuvant treatment in node-negative, postmenopausal breast cancer

      CANCER INVESTIGATION
    16. Edmonson, JH; Suman, VJ; Dalton, RJ; Bro, WC; Gallenberg, MM; Long, HJ; Levitt, R; Hatfield, AK; Krook, JE; Mailliard, JA; Gerstner, JB
      Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: Anorth central cancer treatment group study

      CANCER INVESTIGATION
    17. Lester, EP; Petroni, GR; Barcos, M; Johnson, JL; Millard, FE; Cooper, MR; Omura, GA; Frei, E; Peterson, BA
      Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856

      CANCER INVESTIGATION
    18. Hogberg, T; Glimelius, B; Nygren, P
      A systematic overview of chemotherapy effects in ovarian cancer

      ACTA ONCOLOGICA
    19. Antinori, A; Cingolani, A; Alba, L; Ammassari, A; Serraino, D; Ciancio, BC; Palmieri, F; De Luca, A; Larocca, LM; Ruco, L; Ippolito, G; Cauda, R
      Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy

      AIDS
    20. Garcia-Rayo, S; Perez-Calvo, J; Martin-Algarra, S; Martinez-Monge, R; Fernandez-Hidalgo, O; Subira, L; Martinez-Aguillo, M; Rebollo, J; Azinovic, I; Brugarolas, A
      Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study

      BONE MARROW TRANSPLANTATION
    21. Raabe, A; Quaester, S; Dubben, HH; Zieron, JO; Krull, A; Alberti, W; Beck-Bornholdt, HP
      Impact of treatment acceleration and its timing on the response of the rhabdomyosarcoma R1H of the rat to fractionated irradiation

      STRAHLENTHERAPIE UND ONKOLOGIE
    22. Markman, M; Kennedy, A; Webster, K; Kulp, B; Peterson, G; Belinson, J
      Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m(2) over 3 h) employed in the treatment of gynecologic malignancies

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    23. Madarnas, Y; Sawka, CA; Franssen, E; Bjarnason, GA
      Are medical oncologists biased in their treatment of the large woman with breast cancer ?

      BREAST CANCER RESEARCH AND TREATMENT
    24. Debrix, I; Tilleul, P; Milleron, B; Grene, N; Bouleuc, C; Roux, D; Liote, H; Madelaine, I; Bellanger, A; Conort, O; Fontan, JE; Le Mercier, F; Bardin, C; Becker, A
      The relationship between introduction of American Society of Clinical Oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospital

      CLINICAL THERAPEUTICS
    25. Kraemer, DF; Fortin, D; Doolittle, ND; Neuwelt, EA
      Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (Human non-acquired immunodeficiency syndrome) and survival

      NEUROSURGERY
    26. Cheung, NKV; Kushner, BH; LaQuaglia, M; Kramer, K; Gollamudi, S; Heller, G; Gerald, W; Yeh, S; Finn, R; Larson, SM; Wuest, D; Byrnes, M; Dantis, E; Mora, J; Cheung, IY; Rosenfield, N; Abramson, S; O'Reilly, RJ
      N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age

      MEDICAL AND PEDIATRIC ONCOLOGY
    27. Link, BK; Budd, GT; Scott, S; Dickman, E; Paul, D; Lawless, G; Fridman, M; Ford, J; Carter, WB
      Delivering adjuvant chemotherapy to women with early-stage breast carcinoma - Current patterns of care

      CANCER
    28. Mayers, C; Panzarella, T; Tannock, IF
      Analysis of the prognostic effects of inclusion in a clinical trial and ofmyelosuppression on survival after adjuvant chemotherapy for breast carcinoma

      CANCER
    29. Jeung, HC; Rha, SY; Noh, SH; Min, JS; Kim, BS; Chung, HC
      Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma - 15-year experience at a single institute

      CANCER
    30. Borg, C; Trillet-Lenoir, V
      Introduction to the principles of chemotherapy dose intensity

      BULLETIN DU CANCER
    31. Borg, C; Ligneau, B; Trillet-Lenoir, V
      Dose intensity of chemotherapy in small-cell lung carcinoma

      BULLETIN DU CANCER
    32. Mainwaring, PN; Cunningham, D; Gregory, W; Hoskin, P; Hancock, B; Norton, AJ; MacLennan, K; Smith, P; Hudson, GV; Linch, D
      Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen forpatients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdfiaCEBO versus PMitCEBO

      BLOOD
    33. Unger, C; Haring, B; Kruse, A; Thumann, A; Schneider, B; Clemm, C; Weber, B; Clevert, HD; Hockertz, S; Kalousek, MB
      Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer

      ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
    34. Perez-Calvo, J; Martinez-Aguillo, M; Garcia-Rayo, S; Cajal, TRY; Santisteban, M; Ordonez, JM; Inoges, S; Subira, ML; Martin-Algarra, S; Brugarolas, A
      Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support

      ACTA HAEMATOLOGICA
    35. Pujol, JL; Daures, JP; Riviere, A; Quoix, E; Westeel, V; Quantin, X; Breton, JL; Lemarie, E; Poudenx, M; Milleron, B; Moro, D; Debieuvre, D; Le Chevalier, T
      Etoposide plus cisplatin with or without the combination of 4 '-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French federation of cancer institutes multicenter phase III randomizedstudy

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    36. Hahm, HA; Armstrong, DK; Chen, TL; Grochow, L; Passos-Coelho, J; Goodman, SN; Davidson, NE; Kennedy, MJ
      Novobiocin in combination with high-dose chemotherapy for the treatment ofadvanced breast cancer: A phase 2 study

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    37. Yuen, AR; Fuks, JZ; Ettinger, DS; Chang, AY; Ruckdeschel, JC; Phan, SC; Blum, RH
      Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: An Eastern Cooperative Oncology Group Study (PA586)

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    38. Ozols, RF
      Optimum chemotherapy for ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    39. Ledermann, JA
      High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    40. Masutani, M; Ochi, Y; Kadota, A; Akusawa, H; Kisohara, A; Takahashi, N; Koya, Y; Horie, T
      Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: Randomized trial, can it improve survival of patients with good prognostic factors?

      ONCOLOGY REPORTS
    41. Matsumoto, Y; Deguchi, M; Ishiko, O; Ogita, S
      Retrospective study of the prognostic factors of remission induction for single-agent chemotherapy with cisplatin in advanced epithelial ovarian cancer

      ONCOLOGY REPORTS
    42. Riccardi, A; Tinelli, C; Brugnatelli, S; Pugliese, P; Giardina, V; Giordano, M; Danova, M; Richetti, A; Fava, S; Rinaldi, E; Fregoni, V; Trotti, G; Poli, A
      Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer

      INTERNATIONAL JOURNAL OF ONCOLOGY
    43. Pignata, S; Monfardini, S
      Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma

      EUROPEAN JOURNAL OF CANCER
    44. Pinkerton, CR; Vincent, MPB; Bergeron, C; Fervers, B; Philip, T
      Induction chemotherapy in metastatic neuroblastoma - does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC)

      EUROPEAN JOURNAL OF CANCER
    45. Piccart, MJ; Biganzoli, L; Di Leo, A
      The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

      EUROPEAN JOURNAL OF CANCER
    46. Brown, RSD; Burcombe, RJ; Osborne, ME; Gaze, MN
      Variations in dose and dose intensity of adjuvant CMF chemotherapy for breast cancer throughout the UK

      CLINICAL ONCOLOGY
    47. Fizazi, K; Zelek, L
      Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms

      ANNALS OF ONCOLOGY
    48. Maindrault-Goebel, F; de Gramont, A; Louvet, C; Andre, T; Carola, E; Gilles, V; Lotz, JP; Tournigand, C; Mabro, M; Molitor, JL; Artru, P; Izrael, V; Krulik, M
      Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer

      ANNALS OF ONCOLOGY
    49. Itoh, K; Ohtsu, T; Wakita, H; Igarashi, T; Ishizawa, K; Onozawa, Y; Fujii, H; Minami, H; Sasaki, Y
      Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    50. Niitsu, N; Okamoto, M; Kuraishi, Y; Nakamura, S; Kodama, F; Hirano, M
      CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF)for patients with aggressive non-Hodgkin's lymphoma: a pilot study

      EUROPEAN JOURNAL OF HAEMATOLOGY
    51. Markman, M; Kennedy, A; Webster, K; Peterson, G; Kulp, B; Belinson, J
      Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and Fallopian tube and primary carcinoma of the peritoneum

      JOURNAL OF CLINICAL ONCOLOGY
    52. Extermann, M; Balducci, L; Lyman, GH
      What threshold for adjuvant therapy in older breast cancer patients?

      JOURNAL OF CLINICAL ONCOLOGY
    53. Berry, DA; Muss, HB; Thor, AD; Dressler, L; Liu, ET; Broadwater, G; Budman, DR; Henderson, IC; Barcos, M; Hayes, D; Norton, L
      HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    54. Thor, AD; Liu, S; Edgerton, S; Moore, D; Kasowitz, KM; Benz, CC; Stern, DF; DiGiovanna, MP
      Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    55. Saleh, MN; Sugarman, S; Murray, J; Ostroff, JB; Healey, D; Jones, D; Daniel, CR; LeBherz, D; Brewer, H; Onetto, N; LoBuglio, AF
      Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin inpatients with Lewis Y-expressing epithelial tumors

      JOURNAL OF CLINICAL ONCOLOGY
    56. Massacesi, C; Bascioni, R; Cellerino, R; Scartozzi, M; Bracci, R; Alessandroni, P; Antognoli, S; Ciavattini, A; De Nictolis, M; Piga, A
      Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer

      JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
    57. Gobbi, PG; Broglia, C; Berte, R; Petrilli, MP; Molica, S; Angrilli, F; Iannitto, E; Ghirardelli, ML; Di Renzo, N; Cavanna, L; Ascari, E
      Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease

      HAEMATOLOGICA
    58. Gobbi, PG; Ghirardelli, ML; Avanzini, P; Baldini, L; Quarta, G; Stelitano, C; Broglia, C; Loni, C; Silingardi, V; Ascari, E
      A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian Lymphoma Study Group (GISL)

      HAEMATOLOGICA
    59. Merkle, E; Ackermann, S; Beck, EP; Jager, W; Lang, N
      High-dose versus low-dose cisplatin chemotherapy plus treosulfan in epithelial ovarian carcinoma FIGO II-IV: Results of a prospective randomized trial

      ONKOLOGIE
    60. Woo, IS; Park, YS; Kwon, SH; Park, YL; Lee, JA; Park, MJ; Hyun, IG; Jung, KS; Bae, HS; Oh, DH; Kim, WS; Park, K; Park, CH; Kim, HJ; Ahn, YC
      A phase II study of VP-16-ifosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    61. Han, JY; Kim, KW; Kim, JA; Kang, JH; Jin, JY; Hong, YS; Park, SY; Song, JS; Park, JW; Kim, HK; Lee, KS; Choi, BG
      A phase II study of a daily x4 schedule of vinorelbine plus cisplatin for advanced non-small cell lung cancer

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    62. Mehta, VK; Fisher, GA; Ford, JM; Oberhelman, HA; Vierra, MA; Bastidas, AJ; Poen, JC
      Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    63. Ahn, AB; Ko, WK; Lee, JG; Shim, KY; Jeung, HC; Park, JO; Yoo, NC; Kim, BS; Kim, SK; Kim, SK; Kim, JH
      Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    64. Gatzemeier, U; Kleisbauer, JP; Drings, P; Kaukel, E; Samaras, N; Melo, MJ; Cardenal, F; Robinet, G; Snijder, RJ; von Pawel, J; Palisses, R
      Lenograstim as support for ACE chemotherapy of small-cell lung cancer - A phase III, multicenter, randomized study

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    65. Quantin, X; Riviere, A; Daures, JP; Oliver, P; Comte-Bardonnet, M; Khial, F; Marcillac, I; Pujol, JL
      Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer - Searching for the maximal tolerated dose

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    66. Lyman, GH
      A predictive model for neutropenia associated with cancer chemotherapy

      PHARMACOTHERAPY
    67. Adams, VR
      Adverse events associated with chemotherapy for common cancers

      PHARMACOTHERAPY
    68. Tognoni, A; Pronzato, P; Cadenotti, L; Ghio, E; Manna, N; Pensa, F; Marino, L
      Sequential high dose-density chemotherapy in advanced ovarian cancer

      ANTICANCER RESEARCH
    69. Vigani, A; Pensa, F; Vaira, F; Bancalari, L; Cordani, S; Maggiani, R; Canessa, P; Pronzato, P
      Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer.

      ANTICANCER RESEARCH
    70. Toma, S; Tucci, A; Villani, G; Carteni, G; Spadini, N; Palumbo, R
      Liposomal Doxorubicin (Caelyx) in advanced pretreated Soft Tissue Sarcomas: A phase II study of the Italian Sarcoma Group (ISG)

      ANTICANCER RESEARCH
    71. Trumper, L; Pfreundschuh, M
      The role of treatment duration in chemotherapy regimens for the treatment of malignant diseases

      STRAHLENTHERAPIE UND ONKOLOGIE
    72. van Toorn, DW; Nortier, JWR; Rubach, M; de Swart, CAM; Huldij, JC; van Tinteren, H; Vermorken, JB
      Randomized phase II study of FEC day 1+8 and FEC day 1 in patients with advanced breast cancer

      BREAST CANCER RESEARCH AND TREATMENT
    73. Nistico, C; Garufi, C; Milella, M; Vaccaro, A; D'Ottavio, AM; Fabi, A; Pace, A; Bove, L; Tropea, F; Marsella, A; Izzo, F; D'Attino, RM; Ferraresi, V; De Marco, S; Terzoli, E
      Weekly schedule of vinorelbine in pretreated breast cancer patients

      BREAST CANCER RESEARCH AND TREATMENT
    74. Felgenhauer, J; Hawkins, D; Pendergrass, T; Lindsley, K; Conrad, KU; Miser, JS
      Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas

      MEDICAL AND PEDIATRIC ONCOLOGY
    75. Joly, F; Heron, JF; Kerbrat, P; Chauvergne, J; Rios, M; Mayer, F; Chinet-Charrot, P; Goupil, A; Lebrun-Jezekova, D; Vennin, D; Lhomme, C; Mace-Lesec'h, J; Crouet, H
      High-dose platinum versus standard dose in advanced ovarian carcinoma: A randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)

      GYNECOLOGIC ONCOLOGY
    76. Akerley, W
      Paclitaxel in advanced non-small cell lung cancer - An alternative high-dose weekly schedule

      CHEST
    77. Aslani, A; Smith, RC; Allen, BJ; Pavlakis, N; Levi, JA
      The predictive value of body protein for chemotherapy-induced toxicity

      CANCER
    78. Miller, KD; Munshi, N; Loesch, D; Einhorn, LH; Sledge, GW
      A phase II trial of high dose epirubicin in patients with advanced breast carcinoma

      CANCER
    79. Aglietta, M; Montemurro, F; Fagioli, F; Volta, C; Botto, B; Cantonetti, M; Racanelli, V; Teofili, L; Ferrara, R; Amadori, S; Castoldi, GL; Dammacco, F; Levis, A
      Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease

      CANCER
    80. Bos, AME; de Graaf, H; de Vries, EGE; Piersma, H; Willemse, PHB
      Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer

      BRITISH JOURNAL OF CANCER
    81. Omori, F; Juopperi, T; Chan, CK; Chang, YN; Phipps, S; Nanji, S; Zhao, YJ; Stewart, AK; Dube, ID
      Retroviral-mediated transfer and expression of the multidrug resistance protein 1 gene (MRP1) protect human hematopoietic cells from antineoplastic drugs

      JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH
    82. Tognoni, A; Cadenotti, L; Pensa, F; Vaira, F; Vigani, A; Bancalari, L; Cordani, S; Maggiani, R; Canessa, PA; Pronzato, P
      A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non smallcell lung cancer

      JOURNAL OF CHEMOTHERAPY
    83. Kudelka, AP; Verschraegen, CF; Shen, Y; De Leon, CG; Edwards, CL; Freedman, RS; Forman, A; Gibbs, HR; Mante, R; Hord, M; Canetta, R; Krakoff, I; Kavanagh, JJ
      Long-term results and pharmacokinetics of high-dose paclitaxel in patientswith refractory epithelial ovarian carcinoma

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    84. Focan, C; Levi, F; Kreutz, F; Focan-Henrard, D; Lobelle, JP; Adam, R; Dallemagne, B; Jehaes, C; Markiewicz, S; Weerts, J; Bismuth, H; Jasmin, C; Misset, JL
      Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion

      ANTI-CANCER DRUGS
    85. Philip, PA; Rea, D; Mitchell, K; Carmichael, J; Harris, AL; Talbot, DC
      A pilot study of increasing dose intensity of epirubicin and ifosfamide inpatients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor

      CLINICAL ONCOLOGY
    86. Debrix, I; Madelaine, I; Grenet, N; Roux, D; Bardin, C; Le Mercier, F; Fontan, JE; Connor, O; Pointereau, A; Tilleul, P
      Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals

      PHARMACY WORLD & SCIENCE
    87. Leyvraz, S; Stupp, R
      Little to learn from phase II trials in small-cell lung cancer

      ANNALS OF ONCOLOGY
    88. Jerkeman, M; Anderson, H; Cavallin-Stahl, E; Dictor, M; Hagberg, H; Johnson, A; Kaasa, S; Kvaloy, S; Sundstrom, C; Akerman, M
      CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial

      ANNALS OF ONCOLOGY
    89. Nistico, C; Garufi, C; Barni, S; Frontini, L; Galla, DAP; Giannarelli, D; Vaccaro, A; D'Ottavio, AM; Terzoli, E
      Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer

      ANNALS OF ONCOLOGY
    90. Santoro, A; Balzarotti, M; Tondini, C; Zanini, M; Giardini, R; Latteri, F; Rampinelli, I; Bufalino, R
      Dose-escalation of CHOP in non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    91. Voute, PA; Souhami, RL; Nooij, M; Somers, R; Cortes-Funes, H; van der Eijken, JW; Pringle, J; Hogendoorn, PCW; Kirkpatrick, A; Uscinska, BM; van Glabbeke, M; Machin, D; Weeden, S
      A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma

      ANNALS OF ONCOLOGY
    92. Ozols, RF; Gore, M; Trope, C; Grenman, S
      Intraperitoneal treatment and dose-intense therapy in ovarian cancer

      ANNALS OF ONCOLOGY
    93. Sieger, D; D'Addario, G; Lorenz, U; Bacchi, M; Thurlimann, B
      Dose escalation of carboplatin and cyclophosphamide supported by GM-CSF inthe treatment of patients with advanced ovarian cancer (FIGO III and IV) -a phase I study

      ONKOLOGIE
    94. Kurtz, JE; Deplanque, G; Duclos, B; Giron, C; Lioure, B; Limacher, JM; Herbrecht, R; Laplace, A; Bergerat, JP; Dufour, P
      A phase I/II study of dose-escalated ifosfamide plus carboplatin combination for advanced ovarian carcinoma

      ONKOLOGIE
    95. Cantin, G; L'Esperance, B; Yelle, L; Desjardins, L; Couture, F; Bergeron, M; Lacroix, L; Dufresne, J; Belanger, D; Ouellet, PA; Hewitt, LA; Pirc, L; Gyger, M
      Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    96. Havlin, KA; Ramirez, MJ; Legler, CM; Harris, LN; Matulonis, UA; Hohneker, JA; Hayes, DF; Winer, EP
      Inability to escalate vinorelbine dose intensity using a daily x3 schedulewith and without filgrastim in patients with metastatic breast cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    97. Ozols, R
      Treatment of gynecologic cancer: The US experience

      TUMORI
    98. Cocconi, G; Bella, M; Lottici, R; Leonardi, F; Ceci, G; Passalacqua, R; Di Blasio, B; Bordi, C; Biscottini, B; Melpignano, M; De Biasi, D; Finardi, C; Bacchi, M
      Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    99. Chevreau, C; Bui, BN; Chevallier, B; Krakowski, I; Maugard, C; Mihura, J; Coindre, JM; Gil, B; Cour-Chabernaud, V
      Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS)

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    100. Shochat, E; Hart, D; Agur, Z
      Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols

      MATHEMATICAL MODELS & METHODS IN APPLIED SCIENCES


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/08/20 alle ore 18:01:52